Camrellizumab in the treatment of advanced esophageal squamous cell carcinoma: a real-world study
Latest Information Update: 26 Jul 2021
At a glance
- Drugs Camrelizumab (Primary) ; Angiogenesis inhibitors; Antineoplastics
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Jul 2021 New trial record
- 08 Jun 2021 Results of an exploratory interim analysis (cut-off Dec 2020), presented at the 57th Annual Meeting of the American Society of Clinical Oncology